| PRAME (100-108) HLA-A*0201 peptide, with the sequence VLDGLDVLL, is derived from the Preferentially Expressed Antigen in Melanoma (PRAME) protein. PRAME is a cancer-testis antigen primarily expressed in various tumors, including melanoma, but is absent in most normal tissues except for the testis. It plays a role in inhibiting the retinoic acid receptor (RAR) signaling pathway, which is crucial for cell proliferation, differentiation, and apoptosis. By repressing RAR, PRAME promotes the survival and proliferation of cancer cells.
The peptide VLDGLDVLL is used in immunological research, particularly to stimulate CD8+ T cells in patients with HLA-A*0201, making it valuable in cancer immunotherapy studies. The peptide is often synthesized for use in T cell assays to evaluate immune responses against tumors expressing PRAME.
The molecular weight of this peptide is approximately 956.15 Da, and it is typically used in lyophilized form with a purity of over 95%. PRAME and its associated peptides are studied for their potential in vaccine development, diagnostics, and as therapeutic targets in immunotherapy.
Applications of PRAME (100-108) include use in cancer research, immunology, and therapeutic strategies aimed at boosting the immune system’s ability to recognize and attack cancer cells.
|
